To evaluate the combination of vinorelbine, ifosfamide and cisplatin (VIP) in patients with advanced non-small-cell lung cancer (NSCLC).Seventy-six untreated patients with stages IIIB-IV NSCLC; the chemotherapy regimen consisted of vinorelbine (25 mg/sqm on days 1 and 8), ifosfamide (3 g/sqm on day 1 with uroprotective mesna), and cisplatin (80 mg/sqm on day 1). The cycles were administered on an outpatient basis every 3 weeks.Leukopenia was the most frequent toxicity: grades 3-4 neutropenia was observed in 26\% of the cycles and 19 episodes of febrile neutropenia were reported in 289 evaluable courses. Filgrastim 5 micrograms/kg was administered in 27\% of the courses. Sixty-seven of 76 patients were evaluable for response: the overall response rate was 51\% (95\% confidence interval 35\%-77\%) with 2 complete responses (3\%) and 32 (48\%) partial responses. No significant differences in response rate were observed according to histology or stage of disease. The median time to progression was 6 months (range 1 to 29+) and the median overall survival 10 months (range 1-33+).The combination of vinorelbine, ifosfamide and cisplatin in the dose and schedule employed in this trial shows an interesting response rate with acceptable toxicities. This regimen should be tested in the multimodality therapy of stage IIIA/B NSCLC.

Phase II study of vinorelbine/ifosfamide/cisplatin for the treatment of advanced non-small-cell lung cancer / E., Baldini; C., Tibaldi; A., Chella; C. A., Angeletti; G., Silvano; A., Andrei; R., Algeri; Conte, Pierfranco. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - STAMPA. - 7:(1996), pp. 747-749.

Phase II study of vinorelbine/ifosfamide/cisplatin for the treatment of advanced non-small-cell lung cancer.

CONTE, Pierfranco
1996

Abstract

To evaluate the combination of vinorelbine, ifosfamide and cisplatin (VIP) in patients with advanced non-small-cell lung cancer (NSCLC).Seventy-six untreated patients with stages IIIB-IV NSCLC; the chemotherapy regimen consisted of vinorelbine (25 mg/sqm on days 1 and 8), ifosfamide (3 g/sqm on day 1 with uroprotective mesna), and cisplatin (80 mg/sqm on day 1). The cycles were administered on an outpatient basis every 3 weeks.Leukopenia was the most frequent toxicity: grades 3-4 neutropenia was observed in 26\% of the cycles and 19 episodes of febrile neutropenia were reported in 289 evaluable courses. Filgrastim 5 micrograms/kg was administered in 27\% of the courses. Sixty-seven of 76 patients were evaluable for response: the overall response rate was 51\% (95\% confidence interval 35\%-77\%) with 2 complete responses (3\%) and 32 (48\%) partial responses. No significant differences in response rate were observed according to histology or stage of disease. The median time to progression was 6 months (range 1 to 29+) and the median overall survival 10 months (range 1-33+).The combination of vinorelbine, ifosfamide and cisplatin in the dose and schedule employed in this trial shows an interesting response rate with acceptable toxicities. This regimen should be tested in the multimodality therapy of stage IIIA/B NSCLC.
7
747
749
Phase II study of vinorelbine/ifosfamide/cisplatin for the treatment of advanced non-small-cell lung cancer / E., Baldini; C., Tibaldi; A., Chella; C. A., Angeletti; G., Silvano; A., Andrei; R., Algeri; Conte, Pierfranco. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - STAMPA. - 7:(1996), pp. 747-749.
E., Baldini; C., Tibaldi; A., Chella; C. A., Angeletti; G., Silvano; A., Andrei; R., Algeri; Conte, Pierfranco
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/739336
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 22
social impact